William Blair analyst Myles Minter has maintained their bullish stance on CTNM stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter’s rating is based on Contineum Therapeutics’ strategic focus on advancing its promising clinical asset, PIPE-791, which is poised to initiate a Phase II proof-of-concept trial for idiopathic pulmonary fibrosis (IPF) in the fourth quarter of 2025. This development is seen as a significant opportunity for the company, as nearly 70% of the firm’s fair value is attributed to this asset, highlighting its potential impact on the company’s valuation.
Additionally, the differentiation of PIPE-791 from other LPAR1 antagonists, particularly in terms of safety, adds to its appeal. While there are delays in advancing PIPE-791 for progressive multiple sclerosis (PrMS) and the peripheral LPAR1 antagonist CTX-343, the company’s strategic decision to prioritize later-stage clinical assets and optimize capital allocation is viewed positively. These factors collectively underpin Minter’s Buy rating for Contineum Therapeutics, Inc. Class A stock.
Minter covers the Healthcare sector, focusing on stocks such as Moderna, Arcturus Therapeutics, and Axsome Therapeutics. According to TipRanks, Minter has an average return of 12.1% and a 53.60% success rate on recommended stocks.
In another report released today, JonesTrading also reiterated a Buy rating on the stock with a $23.00 price target.